Below is information about our current clinical trial studies. As with any of our studies at Florida Eye, if you refer patients and they are enrolled, we will update you on the progress of your patient and return the patient to your care at the end of the study. The sponsor covers all expenses and costs of these trials.
Current & Upcoming Clinical Trials
From Dr. Barry Schechter & Dr. Jason Gorscak:
We are no longer enrolling for the dry eye study as it is complete.
We will be doing a study for people needing bilateral cataract surgery for a bioequivalent drug post cataract surgery. Patients are required to have both eyes done within a certain time frame.
From Dr. Katz:
We have one study for wet AMD for sub responders to Lucentis, Avastin, Eyelea or Macugen. This study is for patients who have received 3-10 injections in the past year with the last 3 treatments being with the same drug consistently. Screening is 28-65 of the last injection.
We have a second study for wet AMD using eye drops that cut down on the need for injections. The study combines Lucentis and the study eye drops Squalamine Lactate, which are administered topically. “It is hoped that with the administration of these eye drops twice daily,” says Dr. Katz, “the frequency of intravitreal injections will be greatly reduced.” The study is placebo controlled (for the drops). All get Lucentis but must have insurance to pay for the Lucentis. Participants will receive $50 per visit, no lab and must come for 12 visits over 38 weeks.
We are now enrolling for treatment naïve wet AMD patients for Eyelea. Phase IV, participants are guaranteed to get Eyelea. No AMD in the fellow eye allowed.
A study starting for diabetics who are having cataract surgery and another dry eye study will be starting soon, most likely next month. Stay tuned for more information.
For More Information on Current Trials:
Please contact Debbie Rankin, study coordinator at 1-561-736-5055 or via email at firstname.lastname@example.org.
- Debbie Rankin